
Adults with serious mental illness receive GLP-1 prescriptions at rates similar to or higher than their peers, though schizophrenia continued to lag.
Raptiva for treatment of adult patients (18 years or older) with chronic, moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy






